RBC Capital Maintains QuidelOrtho(QDEL.US) With Buy Rating, Raises Target Price to $62
RBC Capital Reaffirms Their Buy Rating on QuidelOrtho (QDEL)
QuidelOrtho to Report Third Quarter 2024 Financial Results
Wolfe's Tax Loss Selling Stocks Within Communications, Discretionary, Staples, Energy, Financials, Health Care
QuidelOrtho Insider Ups Holding By 54% During Year
QuidelOrtho Announces New R&D Executive Leader
Investors in QuidelOrtho (NASDAQ:QDEL) Have Unfortunately Lost 67% Over the Last Three Years
Cracking The Code: Understanding Analyst Reviews For QuidelOrtho
QuidelOrtho Raised to Neutral From Sell by UBS
RBC Lifts Price Target on QuidelOrtho to $62 From $61, Keeps Outperform Rating
QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer
Why QuidelOrtho Stock Blasted 10% Higher Today
G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday
Craig-Hallum Upgrades QuidelOrtho(QDEL.US) to Buy Rating, Raises Target Price to $57
Express News | QuidelOrtho Corporation : Craig-Hallum Raises Target Price to $57 From $40
Express News | QuidelOrtho Corporation : Craig-Hallum Raises to Buy From Hold
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod
QuidelOrtho Says FDA Approved Syphilis Assay on Disease-Testing Platform
VITROS Syphilis Assay Now Available on VITROS 3600 Immunodiagnostic System, VITROS 5600 and VITROS XT 7600 Integrated Systems in the U.S.